**Core Concept**
The MYD88 L265P mutation is a gain-of-function mutation in the MYD88 gene, leading to the constitutive activation of the NF-κB signaling pathway through the MyD88-dependent pathway. This mutation is associated with the development and progression of certain types of B-cell lymphomas.

**Why the Correct Answer is Right**
The MYD88 L265P mutation occurs in exon 15 of the MYD88 gene, resulting in the substitution of proline for leucine at position 265. This mutation leads to the enhanced interaction between MyD88 and IRAK1, causing the constitutive activation of the IKK complex and subsequent NF-κB activation. This aberrant signaling pathway contributes to the tumorigenesis of lymphomas by promoting cell survival, proliferation, and resistance to apoptosis.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because the MYD88 L265P mutation is not typically associated with chronic lymphocytic leukemia (CLL), although CLL can also involve MYD88 mutations, they are more commonly found in other types of lymphomas.
* **Option B:** This option is incorrect because the MYD88 L265P mutation is not a characteristic feature of follicular lymphoma (FL), although FL can also involve MYD88 mutations, they are more commonly found in other types of lymphomas.
* **Option C:** This option is incorrect because the MYD88 L265P mutation is not typically associated with mantle cell lymphoma (MCL), although MCL can also involve MYD88 mutations, they are more commonly found in other types of lymphomas.

**Clinical Pearl / High-Yield Fact**
The MYD88 L265P mutation is a common genetic alteration in Waldenström macroglobulinemia (WM), a rare type of B-cell lymphoma characterized by the production of IgM monoclonal protein.

**Correct Answer: D. Waldenström macroglobulinemia**